2 recruiting. 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Thymic Neuroendocrine Carcinoma: new trials by email Literature Review of Thymic Neuroendocrine Carcinoma trials Research Report on Thymic Neuroendocrine Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors 225Ac-ETN029, 111In-ETN029 - Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Recruiting | Novartis Pharmaceuticals | 116 | 2025-10-16 | 2026-09-22 |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) individualized mRNA neoantigen vaccine (mRNA-0523-L001) - Adrenal Cortical Carcinoma, Medullary Thyroid Cancer | Not applicable | Recruiting | Shanghai Jiao Tong University School of Medicine | 21 | 2024-01-13 | 2026-04-09 |
Carcinoma, Medullary (2) · Adenoma, Islet Cell (1) · Adrenocortical Carcinoma (1) · Carcinoma, Merkel Cell (1) · Small Cell Lung Carcinoma (1)
Adenocarcinoma (2) · Carcinoma (2) · Carcinoma, Neuroendocrine (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Ductal, Lobular, and Medullary (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Adenoma (1) · Adrenal Cortex Diseases (1) · Adrenal Cortex Neoplasms (1)
Novartis Pharmaceuticals (1) · Shanghai Jiao Tong University School of Medicine (1)
Canada (1) · China (1) · Japan (1) · South Korea (1) · United States (1)